Table 1.
Patient demographics and clinical characteristics.
| Characteristic | Value |
|---|---|
| Age at diagnosis of calciphylaxis (years) | 51.10 ± 14.85 |
| Gender, n (%) | |
| Male | 22 (71%) |
| Female | 9 (29%) |
| BMI | 23.14 ± 3.52 |
| Age at onset of hemodialysis (years) | 47.45 ± 14.83 |
| Duration of dialysis (months) | 74 [48,120] |
| CKD/ESKD/dialysis modality, n (%) | |
| CKD, non-dialysis | 1 (3.23%) |
| Hemodialysis | 30 (96.77%) |
| Peritoneal dialysis | 0 (0%) |
| Vascular access type, n (%) | |
| Arteriovenous fistula | 28 (93.33%) |
| long-term tunneled cuffed catheter | 2 (6.67%) |
| Type of primary kidney disease, n (%) | |
| Others or Unknown | 18 (58.1% |
| Diabetic Nephropathy | 8 (25.8%) |
| Chronic Glomerulonephritis | 4 (12.9%) |
| Hypertensive Nephropathy | 1 (3.2%) |
| Comorbidities, n (%) | |
| Hypertension | 27 (87.10%) |
| Diabetes | 14 (45.16%) |
| Chronic Heart Failure | 9 (29.03%) |
| Autoimmunity Disease | 4 (12.90%） |
| Tumor | 2 (6.45%) |
| Medication history, n (%) | |
| Phosphate binder | 20 (64.52%) |
| Activated vitamin D and its analogues | 16 (51.6%） |
| Cinacalcet | 13 (41.94%) |
| Antithrombotic Drugs | 15 (48.4%) |
Continuous variables are presented as mean ± standard deviation or median [inter-quartile range] when non-normally distributed; categorical variables, as number (percentage).
BMI: body mass index.